Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.
Also called NCT01341613
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 131 participants
- Sponsor
- Micropharma Limited
- Registry
-
NCT01341613
-
- Other papers using this trial's data
- Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial
- Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia
- Registry status
- Completed
Technical summary
Registry record NCT01341613. Randomized; quadruple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2011-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
- Condition
- Hypercholesterolemia
- Intervention (Dietary supplement)
- Cardioviva™ supplement capsule
- Intervention (Dietary supplement)
- Placebo capsule
- Lead sponsor
- Micropharma Limited
Record details
- Record id
cardio:ct-nct01341613- Content hash
29d3ed5fe528f7957d5a4d6ff0d6ddb5079436c6b92d4b202ea88da2dc7b8c2f